Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.

Advertisements

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.

Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.

Subgroup Placebo n/N (%) Serelaxin n/N (%)Favours placeboFavours serelaxin Odds ratio Estimate (95%CI) Interaction P value Total population150/580 (25.9)156/581.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Path to an Angiotensin Receptor Antagonist-Neprilysin.

Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.

The LIVES Sub-analysis

Copyright © 2015 by the American Osteopathic Association.

Fig ACCF/AHA Guideline for the management of heart failure

Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience John J. Sim, MD, Joel Handler, MD, Steven.

Copyright © 2005 American Medical Association. All rights reserved.

FIGURE 1 Flow chart of the study population

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Improving Transitions in CKD: Failure Mode

Figure 1 Energy supply–demand matching in health and heart failure

Viper venom for diabetic nephropathy

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Figure 1 The burden of chronic kidney disease (CKD)

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of cardiovascular medication on the fetus

Fig. 2. Evidence-based medication prescriptions

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Volume 80, Issue 9, Pages (November 2011)

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Volume 84, Issue 1, Pages (July 2013)

Steven J. Rosansky, Richard J. Glassock Kidney International

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Rami Doukky et al. JCHF 2016;4:24-35

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

Ali Ahmed, MD, Gregg C. Fonarow, MD, Yan Zhang, MS, MSPH, Paul W

Methods for guideline development

Volume 81, Issue 7, Pages (April 2012)

Volume 73, Issue 5, Pages (March 2008)

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Volume 81, Issue 12, Pages (June 2012)

Juan Jesús Carrero, PhD American Journal of Kidney Diseases

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.

Percentage of patients found with a kidney function too low for recommended use of the drug using estimated glomerular filtration rate compared with creatinine.

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Glucose-lowering medication in type 2 diabetes: overall approach.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.48 Figure 3 Therapies effective for treating both cardiovascular disease (CVD) and chronic kidney disease (CKD) Figure 3 | Therapies effective for treating both cardiovascular disease (CVD) and chronic kidney disease (CKD). Drugs that improve blood-pressure (BP) control, lipid control, and inhibit the renin–angiotensin–aldosterone system (RAAS) can offer cardiorenal protection in patients with CKD. However, many caveats exist to using these drugs in CKD, including increased risk of hyperkalaemia. ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid-receptor antagonist. Ruiz-Hurtado, G. et al. (2016) Global cardiovascular protection in chronic kidney disease Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.48